Treatment of hereditary epidermolysis bullosa: Updates and future prospects

American Journal of Clinical Dermatology

Volumn 15, Issue 1, 2014, Pages 1-6

  Hsu, Chao Kai ^a   Wang, Sheng Pei ^a   Lee, Julia Yu Yun ^a   McGrath, John A ^b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; EPIDERMOLYSIS BULLOSA HEREDITARIA; FIBROBLAST; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; KERATINOCYTE; MESENCHYMAL STROMA CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN REPLACEMENT THERAPY; SUBSTITUTION THERAPY; TRANSPLANTATION;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; EPIDERMOLYSIS BULLOSA; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENETIC THERAPY; HUMANS; QUALITY OF LIFE;

EID: 84893242547     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0059-z     Document Type: Article

References (37)

1. Bruckner-Tuderman L, McGrath JA, Robinson EC, et al. Progress in Epidermolysis Bullosa Research: Summary of DEBRA International Research Conference 2012. J Invest Dermatol. 2013;133:2121-6.
2. Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58:931-50.
3. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009;61:387-402.
4. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61:367-84.
5. Varki R, Sadowski S, Uitto J, et al. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J Med Genet. 2007;44:181-92.
6. McGrath JA, Ishida-Yamamoto A, O'Grady A, et al. Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression. J Invest Dermatol. 1993;100:366-72.
7. Chung HJ, Uitto J. Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa. Dermatol Clin. 2010;28:93-105.
8. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12:1397-402.
9. U.S. National Institutes of Health. Gene transfer for recessive dystrophic epidermolysis bullosa. http://clinicaltrials.gov/ct2/show/ NCT01263379?term=NCT01263379&rank=1. Accessed Oct 2013.
10. Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636-46.
11. Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188:773-82.
12. Osborn MJ, Starker CG, McElroy AN, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 2013;21:1151-9.
13. Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med. 2004;10:693-5.
14. Woodley DT, Wang X, Amir M, et al. Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol. 2013;133:1910-3.
15. Palazzi X, Marchal T, Chabanne L, et al. Inherited dystrophic epidermolysis bullosa in inbred dogs: a spontaneous animal model for somatic gene therapy. J Invest Dermatol. 2000;115:135-7.
16. Cogan J, Wang XY, Hou YP, Khilili M, Woodley DT, Chen M. Epitope mapping of anti-type VII collagen antibodies in the patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2013;133:S45.
17. Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008;128:2179-89.
18. Nagy N, Almaani N, Tanaka A, et al. HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa. J Invest Dermatol. 2011;131:1771-4.
19. Kern JS, Loeckermann S, Fritsch A, et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther. 2009;17:1605-15.
20. Fritsch A, Loeckermann S, Kern JS, et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008;118:1669-79.
21. Venugopal SS, Yan W, Frew JW, et al. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013;69:898-908.
22. Petrof G, Martinez-Quiepo M, Mellerio JE, et al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomised, vehicle-controlled trial. Br J Dermatol. 2013;169:1025-33.
23. Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010;12:429-31.
24. Tamai K, Yamazaki T, Chino T, et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A. 2011;108:6609-14.
25. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363:629-39.
26. Almaani N, Nagy N, Liu L, Dopping-Hepenstal PJ, et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2010;130:1937-40.
27. Jonkman MF, Scheffer H, Stulp R, et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 1997;88:543-51.
28. Lai-Cheong JE, McGrath JA. Revertant mosaicism in the skin. G Ital Dermatol Venereol. 2013;148:73-82.
29. Pasmooij AMG, Jonkman MF, Uitto J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov Med. 2012;14:167-79.
30. Pasmooij AM, Nijenhuis M, Brander R, et al. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations. J Invest Dermatol. 2012;132:1374-83.
31. Gostyński A, Llames S, García M, et al. Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy. J Invest Dermatol. 2013. doi: 10.1038/jid.2013.308
32. Gostynski A, Deviaene FC, Pasmooij AM, et al. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br J Dermatol. 2009;161:444-7.
33. Gostynski A, Bremer J, Huizinga J, et al. Successful therapeutic transplantation of revertant skin in a patient with epidermolysis bullosa. J Invest Dermatol. 2013;133:S132.
34. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
35. Tolar J, Xia L, Riddle MJ, Lees CJ, et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2011;131:848-56.
36. Itoh M, Kiuru M, Cairo MS, et al. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2011;108:8797-802.
37. Umegaki N, Guo Z, Itoh M, et al. Generation of induced pluripotent stem cells from revertant mosaic keratinocytes: a novel strategy for natural gene therapy for epidermolysis bullosa. J Invest Dermatol. 2013;133:S243-6.